CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India
-
Sep 2021
-
-
Source: Emerg Infect Dis. 27(9):2349-2359
[PDF-2.32 MB]
Details:
-
Alternative Title:Emerg Infect Dis
-
Personal Author:
-
Corporate Authors:
-
Description:During September-December 2020, we conducted a multicenter retrospective study across India to evaluate epidemiology and outcomes among cases of coronavirus disease (COVID-19)-associated mucormycosis (CAM). Among 287 mucormycosis patients, 187 (65.2%) had CAM; CAM prevalence was 0.27% among hospitalized COVID-19 patients. We noted a 2.1-fold rise in mucormycosis during the study period compared with September-December 2019. Uncontrolled diabetes mellitus was the most common underlying disease among CAM and non-CAM patients. COVID-19 was the only underlying disease in 32.6% of CAM patients. COVID-19-related hypoxemia and improper glucocorticoid use independently were associated with CAM. The mucormycosis case-fatality rate at 12 weeks was 45.7% but was similar for CAM and non-CAM patients. Age, rhino-orbital-cerebral involvement, and intensive care unit admission were associated with increased mortality rates; sequential antifungal drug treatment improved mucormycosis survival. The COVID-19 pandemic has led to increases in mucormycosis in India, partly from inappropriate glucocorticoid use.
-
Subjects:
-
Source:
-
Pubmed ID:34087089
-
Pubmed Central ID:PMC8386807
-
Document Type:
-
Place as Subject:
-
Location:
-
Volume:27
-
Issue:9
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
